tirzepatide bump at injection site GLP-1 reaction: causes, symptoms, and how to treat every type Where you inject matters more

Overview of Clinical Studies Clinical studies on semaglutide have primarily focused on its efficacy in managing type 2 diabetes and obesity

Bibcode:2000Sci...289.1567M

The average weight loss of patients with a 2.4 mg semaglutide dose reached 9.6% after 12 weeks, 13.8% after six months, and approximately 15% to 20% after a year

Tumour necrosis factor (TNF) released from microglia or perivascular macrophages activates the c-Jun N-terminal kinase (JNK) and inhibitor of B alpha/nuclear factor B (IB/NF-B) signalling pathways, thereby amplifying neuroinflammatory responses throughout the brain parenchyma [8]

In some cases, a plateau occurred around months 34

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP-8)